Abstract
Subnormal plasma levels of high-density lipoprotein cholesterol (HDL-C) constitute a major cardiovascular risk factor. Raising low HDL-C levels may therefore reduce the residual cardiovascular risk that frequently presents in dyslipidaemic subjects. The activity of Cholesteryl ester transfer protein (CETP) is levated in the dyslipidaemias of metabolic disease involving insulin resistance, hypertriglyceridaemia, and leads premature atherosclerosis and high cardiovascular risk. CETP inhibition therefore is regarded as a potential target for elevation of HDL-C and reduction in atherosclerosis. Treatment with Anacetrapib that a CETP inhibitor had strong effects on low-density lipoprotein (LDL) and HDL-C, according to recent study. Further studies of Anacetrapib, specifically in long-term, large-scale outcome trials, will provide essential information on its safety and efficacy in reducing residual cardiovascular risk.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
